Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00182806
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • gemcitabine hydrochloride — DRUG
    IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
  • irinotecan hydrochloride — DRUG
    IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Irinotecan may also increase the effectiveness of gemcitabine. Giving irinotecan together with gemcitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with gemcitabine works in treating patients with recurrent or progressive stage III or stage IV non-small cell lung cancer.

Key Dates

Start date
Sep 30, 2004
Status verified
Mar 2012
Primary completion
Sep 30, 2007
Completion
Jul 31, 2008

Study Design

Enrollment
38 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective response (complete, partial, and stable disease)

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies